Screener

Total revenues and income

Ligand Pharmaceuticals·Products & Services·18 segments·Rolls up to Total Revenue

Breakdown

Segment	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26
Filspari	$3.21M	$4.78M	$5.3M	$6.58M	$9.08M	$11.01M	$11.32M	$13.57M
Captisol	$6.26M	$7.92M	$13.46M	$8.29M	$10.67M	$7.79M	$8.65M	$7.98M
Qarziba	—	—	$5.44M	$5.89M	$5.98M	$6.44M	$6.3M	$6.15M
Income	$0	—	$0	$1.02M	$5M	—	—	$5M
Other	—	—	$3.67M	$2.56M	$3.42M	—	$3.76M	$4.27M
Ohtuvayre	—	—	—	—	—	—	$2.99M	$4.14M
Ohtuvayre inventors	—	—	—	—	—	—	$3.05M	$3.29M
Rylaze	$3.89M	$3.67M	$3.12M	$2.86M	$3.56M	$3.81M	$3.22M	$3.2M
Contract revenue	$13.85M	$2.03M	$4.38M	$1.93M	$131K	$60.43M	$110K	$2.68M
Capvaxive	—	—	—	—	$3.21M	$3.72M	$1.97M	$2.32M
Teriparatide injection	$2.38M	$1.7M	$1.19M	$2.3M	$2.63M	$2.03M	$1.32M	$1.47M
Vaxneuvance	$1.47M	$1.22M	$1.29M	$2.64M	$2.04M	$1.44M	$1.61M	$1.35M
Contract revenue and income	$6.87M	$6.87M	$4.38M	$2.94M	—	—	—	—
Evomela	$2.17M	$2.17M	$1.49M	$1.49M	$1.49M	$1.49M	—	—
Income from financial royalty assets	$5.16M	$6.99M	—	—	—	—	—	—
Kyprolis	$9.59M	$9.59M	$8.88M	$8.88M	$8.88M	$8.88M	—	—
Revenue from intangible royalty assets	$26.55M	$27.82M	—	—	—	—	—	—
Total	$51.81M	$42.81M	$45.33M	$47.63M	$115.46M	$59.67M	$51.72M	$63.69M